ABSTRACT
ABSTRACT: Immunoglobulin A nephropathy (IgAN) is a form of chronic glomerulonephritis that can cause end-stage renal disease. Recently, tonsillectomy combined with corticosteroid pulse (TSP) has been shown to be effective for achieving clinical remission and favorable renal outcome in patients with IgAN. However, the standard regimen of corticosteroid use in TSP has not been established. Herein, we compared the effect of single- or triple-course steroid pulse therapy combined with tonsillectomy in patients with IgAN.This retrospective, observational cohort study included 122 patients with IgAN enrolled from January 2004 to December 2018 at 2 independent institutions. We divided the patients into 2 groups; single-course (TSP1: nâ=â70) and triple-course (TSP3: nâ=â52) of corticosteroid pulse therapy (1 course comprised 3 consecutive days' infusion of 0.5âg methylprednisolone) combined with tonsillectomy. The primary outcome for renal survival was defined as the first occurrence of â§30% decrease in estimated glomerular filtration rate from baseline. Secondary outcomes included the incidence of clinical remission and recurrence of the disease.Regarding clinical parameters and findings at baseline, there were no significant differences between the 2 groups. The 8-years renal survival in the 2 groups was not significantly different according to Kaplan-Meier curves (TSP1; 82.5% vs TSP3; 69.2%, log-rank test Pâ=â.39). The cumulative incidence rates of remission of hematuria (94.4% vs 85.4%, Pâ=â.56) and clinical remission (85.0% vs 64.8%, Pâ=â.07) were comparable in both groups, while those of proteinuria showed higher rates in TSP1 than TSP3 (88.4% vs 65.4%, Pâ=â.02). The cumulative incidence of relapse of hematuria (5.6% vs 2.3%, Pâ=â.42) and proteinuria (7.1% vs 3.3%, Pâ=â.41) showed no significant differences in the 2 groups. Cox regression analyses showed that the number of courses of corticosteroid pulse therapy was not significantly associated with renal outcome (TSP1 vs TSP3; Hazard ratios 0.69, 95% confidence intervals 0.29-1.64, Pâ=â.39).The effect of single-course corticosteroid pulse therapy is not statistically, significantly different from triple-course in TSP protocol for improving renal outcome and preventing relapse in patients with IgAN. Single-course corticosteroid pulse therapy may become a treatment option for patients with IgAN.
Subject(s)
Adrenal Cortex Hormones/therapeutic use , Glomerulonephritis, IGA/drug therapy , Glomerulonephritis, IGA/surgery , Methylprednisolone/therapeutic use , Pulse Therapy, Drug/methods , Tonsillectomy , Adrenal Cortex Hormones/administration & dosage , Adult , Female , Hematuria , Humans , Male , Methylprednisolone/administration & dosage , Middle Aged , Proteinuria , Recurrence , Remission Induction , Retrospective Studies , Steroids/therapeutic use , Treatment OutcomeABSTRACT
We report about the usefulness of F-FDG PET for the detection and therapy response evaluation of renal sarcoidosis. A 55-year-old woman presented with a condition diagnosed with pulmonary and ocular sarcoidosis 2 years before having anemia and acute deterioration of renal function. FDG PET revealed diffuse increased FDG uptake in both kidneys and the spleen. Histopathologic examination of a renal biopsy sample revealed granulomatous interstitial nephritis with sarcoidosis. After methylprednisolone treatment, the abnormal FDG uptake resolved completely with improvement of symptoms. FDG PET is a useful tool to detect active sarcoidosis regions and to monitor treatment efficacy.